Abstract
Extended survival of 3 or more years is rare in patients with glioblastoma (GBM) but is becoming more common. Clinical outcome has not been well studied. We reviewed GBM patients at Memorial Sloan-Kettering Cancer Center between 2001 and 2003 who were seen for two or more visits. Patient characteristics and long-term clinical outcomes were reviewed for patients who had survived 3 or more years following diagnosis. Thirty-nine (11%) of 352 GBM patients were identified as long-term survivors. Median survival was 9.15 years (range: 3–18 years). Median age was 47 years (range: 16–69); 13% were 65 years or older. Median KPS was 90 (range: 50–100). One long-term survivor underwent biopsy alone; 19 patients each had either complete or subtotal resection. All received focal radiotherapy (RT) with a median dose of 5940 cGy; 18% received concurrent temozolomide. Adjuvant chemotherapy was administered to 35 (90%). Twelve patients (31%) remained in continuous remission. Twenty-seven had tumor progression a median of 29.2 months after diagnosis (range: 1.2–167 months); 18 had multiple relapses. Median KPS at last follow-up was 70 (range: 40–100); 85% of long-term survivors had at least one significant neurologic deficit. Eleven (28%) had clinically significant RT-induced leukoencephalopathy, 9 (23%) developed RT necrosis and 9 (23%) treatment-related strokes. Treatment-related complications occurred a median of 2.7 years from diagnosis (range: 0.9–11.5 years). Long-term survivors remain rare, but are found across all age groups despite multiple recurrences; clinically significant delayed complications of treatment are common.
Similar content being viewed by others
References
DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Schmidinger M, Linzmayer L, Becherer A, Fazeny-Doemer B, Fakhrai N, Prayer D, Killer M, Ungersboeck K, Dieckmann K, Marosi C (2003) Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J Neuro-oncol 63:55–61
Chandler KL, Prados MD, Malec M, Wilson CB (1993) Long-term survival in patients with glioblastoma multiforme. Neurosurgery 32:716–720 (discussion 720)
Morita M, Rosenblum MK, Bilsky MH, Fraser RA, Rosenfeld MR (1996) Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neuro-oncol 27:259–266
Salford LG, Brun A, Nirfalk S (1988) Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 69:506–509
Scott JN, Rewcastle NB, Brasher PM, Fulton D, Hagen NA, MacKinnon JA, Sutherland G, Cairncross JG, Forsyth P (1998) Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci 25:197–201
Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, Passe S, Jenkins RB, Aldape KD (2002) Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 62:6205–6210
Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M (1987) Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21:201–206
Scheibel RS, Meyers CA, Levin VA (1996) Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neuro-oncol 30:61–69
Taylor BV, Buckner JC, Cascino TL, O’Fallon JR, Schaefer PL, Dinapoli RP, Schomberg P (1998) Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol 16:2195–2201
Muller H, Brock M, Ernst H (1985) Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas. Clin Neurol Neurosurg 87:167–171
Salcman M, Scholtz H, Kaplan RS, Kulik S (1994) Long-term survival in patients with malignant astrocytoma. Neurosurgery 34:213–219 (discussion 219–220)
Stupp R, Hegi ME, Mason WP, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol [Epub ahead of print]
Bahr O, Herrlinger U, Weller M, Steinback JP (2009) Very late relapses in glioblastoma long-term survivors. J Neurol [Epub ahead of print]
Krex D, Klink B, Hartmann C et al (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596–2606
Steinbach JP, Blaicher H-P, Herrlinger U et al (2006) Surviving glioblastoma for more than 5 years: the patient’s prospective. Neurology 66:239–242
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hottinger, A.F., Yoon, H., DeAngelis, L.M. et al. Neurological outcome of long-term glioblastoma survivors. J Neurooncol 95, 301–305 (2009). https://doi.org/10.1007/s11060-009-9946-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-009-9946-9